Cancer Biologics Market
Cancer Biologics Market - Global Industry Assessment & Forecast
#
Pages:
149
Base Year:
2023
Jun - 2024
Format:
Report Code:
VMR-2506
Segments Covered
By
Drug Class Monoclonal Antibodies, Cancer Growth Inhibitors, Vaccines, Recombinants Proteins , CAR-T Cells, Angiogenesis Inhibitors, Interleukins (IL), Interferons (IFN), Gene Therapy, Other Drug Classes
-
By
Application Blood Cancer, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Gastric Cancer, Ovarian Cancer, Skin Cancer, Liver Cancer, Other Applications
-
By
End Use Hospitals, Cancer Center, Academics & Research Institutes
-
By
Region North America , Europe , Asia Pacific, Latin America, Middle East & Africa
Snapshot
 Base Year:
|
2023 |
| Forecast
Years:
|
2024 - 2032 |
 Historical
Years:
|
2018 - 2022 |
 Revenue
2023: |
USD 109.1 Billion |
 Revenue 2032:
|
USD 197.1 Billion |
 Revenue CAGR
(2024 - 2032): |
6.79% |
Fastest Growing Region (2024 -
2032)
|
Asia Pacific |
Largest Region (2023):
|
North America |
Customization Offered
Cross-segment Market Size and
Analysis
for Mentioned Segments- Additional Company Profiles (Upto 5
With
No Cost)
- Additional Countries (Apart From
Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request
Customization Speak To
Analyst
Cancer Biologics Market Segment Analysis
- Cancer Biologics Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- Cancer Biologics Application Outlook (Revenue, USD Million, 2018 - 2030)
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- Cancer Biologics End Use Outlook (Revenue, USD Million, 2018 - 2030)
- Hospitals
- Cancer Center
- Academics & Research Institutes
-
Regional Outlook (Revenue, USD Billion/Million, 2018 - 2030)
- North America
-
North America Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
-
North America Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
-
North America Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- U.S.
- U.S. Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- U.S. Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- U.S. Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- U.S. Cancer Biologics Market, by Drug Class
- Canada
- Canada Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- Canada Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- Canada Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- Canada Cancer Biologics Market, by Drug Class
-
Mexico
- Mexico Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- Mexico Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- Mexico Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- Mexico Cancer Biologics Market, by Drug Class
-
North America Cancer Biologics Market, by Drug Class
- Europe
-
Europe Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
-
Europe Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
-
Europe Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- U. K.
- U.K. Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- U.K. Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- U.K. Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- U.K. Cancer Biologics Market, by Drug Class
- France
- France Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- France Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- France Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- France Cancer Biologics Market, by Drug Class
-
Germany
- Germany Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- Germany Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- Germany Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- Germany Cancer Biologics Market, by Drug Class
-
Italy
- Italy Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- Italy Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- Italy Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- Italy Cancer Biologics Market, by Drug Class
-
Spain
- Spain Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- Spain Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- Spain Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- Spain Cancer Biologics Market, by Drug Class
-
Rest of Europe
- Rest of Europe Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- Rest of Europe Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- Rest of Europe Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- Rest of Europe Cancer Biologics Market, by Drug Class
-
Europe Cancer Biologics Market, by Drug Class
- Asia Pacific
-
Asia Pacific Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
-
Asia Pacific Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
-
Asia Pacific Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- China
- China Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- China Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- China Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- China Cancer Biologics Market, by Drug Class
- Japan
- Japan Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- Japan Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- Japan Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- Japan Cancer Biologics Market, by Drug Class
-
Germany
- Germany Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- Germany Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- Germany Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- Germany Cancer Biologics Market, by Drug Class
-
India
- India Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- India Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- India Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- India Cancer Biologics Market, by Drug Class
-
South Korea
- South Korea Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- South Korea Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- South Korea Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- South Korea Cancer Biologics Market, by Drug Class
-
South East Asia
- South East Asia Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- South East Asia Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- South East Asia Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- South East Asia Cancer Biologics Market, by Drug Class
-
Rest of Asia Pacific
- Rest of Asia Pacific Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- Rest of Asia Pacific Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- Rest of Asia Pacific Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- Rest of Asia Pacific Cancer Biologics Market, by Drug Class
-
Asia Pacific Cancer Biologics Market, by Drug Class
- Latin America
-
Latin America Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
-
Latin America Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
-
Latin America Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- Brazil
- Brazil Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- Brazil Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- Brazil Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- Brazil Cancer Biologics Market, by Drug Class
- Argentina
- Argentina Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- Argentina Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- Argentina Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- Argentina Cancer Biologics Market, by Drug Class
-
Rest of Latin America
- Rest of Latin America Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- Rest of Latin America Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- Rest of Latin America Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- Rest of Latin America Cancer Biologics Market, by Drug Class
-
Latin America Cancer Biologics Market, by Drug Class
- Middle East & Africa
-
Middle East & Africa Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
-
Middle East & Africa Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
-
Middle East & Africa Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- GCC Countries
- GCC Countries Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- GCC Countries Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- GCC Countries Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- GCC Countries Cancer Biologics Market, by Drug Class
- South Africa
- South Africa Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- South Africa Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- South Africa Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- South Africa Cancer Biologics Market, by Drug Class
-
Rest of Middle East & Africa
- Rest of Middle East & Africa Cancer Biologics Market, by Drug Class
- Monoclonal Antibodies
- Cancer Growth Inhibitors
- Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Other Drug Classes
- Rest of Middle East & Africa Cancer Biologics Market, by Application
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Other Applications
- Rest of Middle East & Africa Cancer Biologics Market, by End Use
- Hospitals
- Cancer Center
- Academics & Research Institutes
- Rest of Middle East & Africa Cancer Biologics Market, by Drug Class
-
Middle East & Africa Cancer Biologics Market, by Drug Class
- North America
Vantage Market
Research | 26-Jun-2024
FAQ
Frequently Asked Question
What is the global demand for Cancer Biologics in terms of revenue?
-
The global Cancer Biologics valued at USD 109.1 Billion in 2023 and is expected to reach USD 197.1 Billion in 2032 growing at a CAGR of 6.79%.
Which are the prominent players in the market?
-
The prominent players in the market are Abbott Laboratories (U.S.), Angel Pharmaceuticals (China), Amgen Inc. (U.S.), AstraZeneca (UK), BioNTech (Germany), Bristol-Mayer Squibb Company (U.S.), Dr. Reddy's Laboratories (India), Duality Biologics (China), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland).
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 6.79% between 2024 and 2032.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Cancer Biologics include
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Cancer Biologics in 2023.
